Avelumab (Bavencio)

General information

Class/mechanism: PD-L1 blocking antibody. PD-L1 (programmed death-1 ligand 1) expressed on tumor cells and tumor-infiltrating immune cells can result in inhibition of anti-tumor immune responses. Avelumab binds to PD-1 and B7.1 receptors on T-cells and antigen presenting cells and prevents PD-L1's inhibitory effects on the immune system. As a result, avelumab stimulates immune responses, including anti-tumor immune effects.^[1]^[2]^[3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Toxicity management

Immunotherapy toxicity management

Diseases for which it is established (work in progress)

Patient drug information

History of changes in FDA indication

Bladder cancer

2017-05-09: Granted accelerated approval for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. (Based on JAVELIN Solid Tumor)
- 2020-06-30: Full approval for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. (Converted to regular approval; expanded to maintenance setting; based on JAVELIN Bladder 100)

Merkel cell carcinoma

2017-03-23: Initial accelerated approval for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma (MCC). (Based on JAVELIN Merkel 200)

Renal cell carcinoma

2019-05-14: Approved in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma (RCC). (Based on JAVELIN Renal 101)

History of changes in Health Canada indication

2017-12-18: Initial notice of compliance with conditions for the treatment of metastatic Merkel Cell Carcinoma (MCC) in previously treated adults.
- 2021-01-13: Conditions were met
2018-05-04: Notice of compliance with conditions for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy.
- 2019-05-14: Conditions were met
2019-11-06: New indication for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC)
2020-12-10: New indication for the maintenance treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed following first-line platinum-based chemotherapy.

History of changes in PMDA indication

2017-09-27: New approval for the treatment of unresectable Merkel cell carcinoma.
2019-12-20: new indication and a new dosage for the treatment of unresectable or metastatic renal cell carcinoma.
2021-02-24: new indication for the maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy.

Also known as

Code name: MSB0010718C
Brand name: Bavencio

References

[insert-1] 1.0 ^1.1 ^1.2 Avelumab (Bavencio) package insert

[2] Avelumab (Bavencio) package insert (locally hosted backup)

[3] Bavencio manufacturer's website

[4] Avelumab (Bavencio) patient drug information (Chemocare)

[5] Avelumab (Bavencio) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

[5]